Briefs: Panacea Biotec and Shukra Pharmaceuticals

Panacea Biotec receives acceptance from CMSS for supply of bOPV

Biocon Biologics secures US market entry date for Bosaya and Aukelso, Denosumab biosimilars

GSK names Luke Miels as next CEO

Miels will formally assume the role on January 1, 2026

Moderna opens manufacturing and R&D facility in UK

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population

Croda expanded UK facility, invests in biopharma innovation

The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)

Shukra Pharmaceuticals bags Rs. 24 crore medicines supply contract from HSCC India

MHRA approves UK’s first new type of antibiotic for urinary tract infections

As with any medicine, the MHRA will keep the safety of gepotidacin under close review

CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA

Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission